Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLT OTCMKTS:BIXT NASDAQ:INAB NASDAQ:PASG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.10$0.10$0.09▼$1.50$15.86M2.087.28 million shsN/ABIXTBioxytran$0.03-5.2%$0.04$0.03▼$0.17$3.94M1.9583,667 shs4,000 shsINABIN8bio$1.49-6.3%$1.58$1.17▼$5.61$15.66M0.0857,458 shs130,756 shsPASGPassage Bio$5.22-2.6%$7.31$3.93▼$20.00$17.19M1.38160,071 shs42,443 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%0.00%+0.00%+0.00%-78.77%BIXTBioxytran-5.17%-4.90%-10.81%-32.10%-68.39%INABIN8bio-6.29%-5.70%+6.43%-16.29%-66.14%PASGPassage Bio-2.61%+23.99%-56.10%-40.75%-2.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.10$0.10$0.09▼$1.50$15.86M2.087.28 million shsN/ABIXTBioxytran$0.03-5.2%$0.04$0.03▼$0.17$3.94M1.9583,667 shs4,000 shsINABIN8bio$1.49-6.3%$1.58$1.17▼$5.61$15.66M0.0857,458 shs130,756 shsPASGPassage Bio$5.22-2.6%$7.31$3.93▼$20.00$17.19M1.38160,071 shs42,443 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%0.00%+0.00%+0.00%-78.77%BIXTBioxytran-5.17%-4.90%-10.81%-32.10%-68.39%INABIN8bio-6.29%-5.70%+6.43%-16.29%-66.14%PASGPassage Bio-2.61%+23.99%-56.10%-40.75%-2.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 1.67Reduce$1.00870.87% UpsideBIXTBioxytran 0.00N/AN/AN/AINABIN8bio 2.00Hold$4.00168.46% UpsidePASGPassage Bio 2.14Hold$13.25153.83% UpsideCurrent Analyst Ratings BreakdownLatest BIXT, PASG, APLT, and INAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026INABIN8bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PASGPassage Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$21.00 ➝ $7.004/21/2026PASGPassage Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$21.00 ➝ $7.004/21/2026PASGPassage Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$30.00 ➝ $15.004/21/2026PASGPassage Bio TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/21/2026PASGPassage Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$32.00 ➝ $8.004/20/2026PASGPassage Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageReduce4/20/2026PASGPassage Bio Lucid Cap MktsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/31/2026PASGPassage Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$30.003/27/2026PASGPassage Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/13/2026INABIN8bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$1M15.86N/AN/A$0.49 per share0.21BIXTBioxytranN/AN/AN/AN/A($0.02) per shareN/AINABIN8bioN/AN/AN/AN/A$2.31 per shareN/APASGPassage BioN/AN/AN/AN/A$3.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$105.62M-$0.10N/AN/AN/AN/A-340.84%-175.00%N/ABIXTBioxytran-$2.12M-$0.02N/AN/AN/AN/AN/A-798.66%N/AINABIN8bio-$19.44M-$2.61N/AN/AN/AN/A-96.39%-80.18%N/APASGPassage Bio-$45.52M-$14.48N/AN/AN/AN/A-150.88%-59.78%7/30/2026 (Estimated)Latest BIXT, PASG, APLT, and INAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BIXTBioxytranN/A-$0.02N/A-$0.02N/AN/A5/12/2026Q1 2026PASGPassage Bio-$2.7640-$2.36+$0.4040-$2.36N/AN/A5/7/2026Q1 2026INABIN8bio-$0.59-$0.26+$0.33-$0.26N/AN/A3/12/2026Q4 2025INABIN8bio-$0.18-$0.26-$0.08-$0.26N/AN/A3/3/2026Q4 2025PASGPassage Bio-$2.19-$4.08-$1.89-$4.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ABIXTBioxytranN/AN/AN/AN/AN/AINABIN8bioN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A0.960.96BIXTBioxytranN/A0.160.16INABIN8bioN/A10.5010.50PASGPassage BioN/A1.732.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%BIXTBioxytranN/AINABIN8bio92.05%PASGPassage Bio53.48%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics1.60%BIXTBioxytran70.00%INABIN8bio14.50%PASGPassage Bio4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30153.96 million151.50 millionOptionableBIXTBioxytran2113.36 million34.01 millionNot OptionableINABIN8bio209.85 million8.42 millionNot OptionablePASGPassage Bio1303.21 million3.05 millionNo DataBIXT, PASG, APLT, and INAB HeadlinesRecent News About These CompaniesPassage Bio (PASG) to Release Earnings on TuesdayMay 10, 2026 | americanbankingnews.comPassage Bio (PASG) price target decreased by 62.83% to 11.63April 28, 2026 | msn.comTD Cowen downgrades Passage Bio (PASG)April 23, 2026 | msn.comPassage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate UpdatesApril 20, 2026 | globenewswire.comPassage Bio (PASG) Gets a Buy from Chardan CapitalApril 8, 2026 | theglobeandmail.comOppenheimer initiates coverage of Passage Bio (PASG) with outperform recommendationApril 1, 2026 | msn.comPassage Bio (PASG) price target decreased by 22.22% to 31.42March 28, 2026 | msn.comPassage Bio advances frontotemporal dementia trial and reports 2025 resultsMarch 10, 2026 | msn.comPassage Bio Ends Hopewell Lab Lease, Extends Cash RunwayMarch 10, 2026 | tipranks.comAnalysts Are Bullish on These Healthcare Stocks: Esperion (ESPR), Passage Bio (PASG)March 8, 2026 | theglobeandmail.comPassage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business HighlightsMarch 3, 2026 | globenewswire.comPassage Bio management to present at two healthcare conferencesFebruary 24, 2026 | msn.comPassage Bio to Participate in Upcoming Investor ConferencesFebruary 19, 2026 | globenewswire.comPassage Bio (NASDAQ:PASG) CEO Sells $75,161.44 in StockJanuary 13, 2026 | insidertrades.comFinancial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG)December 7, 2025 | defenseworld.netDPassage Bio (PASG) price target increased by 21.85% to 40.39December 7, 2025 | msn.comPassage Bio initiated with a Buy at Lucid CapitalNovember 24, 2025 | msn.comPassage Bio (PASG) Price Target Decreased by 45.15% to 33.15November 17, 2025 | msn.comPassage Bio reports Q3 EPS ($2.44), consensus ($2.97)November 11, 2025 | msn.comPassage Bio, Inc. Announces Active Enrollment in upliFT-D Study and Regulatory Alignment with FDANovember 10, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIXT, PASG, APLT, and INAB Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.10 0.00 (0.00%) As of 05/14/2026Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Bioxytran OTCMKTS:BIXT$0.03 0.00 (-5.17%) As of 05/15/2026 01:00 PM EasternBioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.IN8bio NASDAQ:INAB$1.49 -0.10 (-6.29%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.53 +0.04 (+2.48%) As of 05/15/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications. Passage Bio NASDAQ:PASG$5.22 -0.14 (-2.61%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$5.35 +0.13 (+2.49%) As of 05/15/2026 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
